The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A new rating scale for Alzheimer's disease
Abstract
A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent meta-analysis showed that CS has a moderate effect size on the Mini Mental State Examination (75) and a small effect size on the Alzheimer's Disease Assessment Scale-cognitive subscale (76), which represent two commonly-used general cognitive functioning outcomes, in patients with dementia (73).”
From The Multidisciplinary Approach to Alzheimer’s Disease and Dementia. A Narrative Review of Non-Pharmacological Treatment (2018) · cites this paper as [76]
Citations
Cites
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Self-citationShader, R. I., Harmatz, J. S., & Salzman, C. (1974) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1974.tb01521.x · Cited by 307
Effects of Naloxone in Senile Dementia: A Double-Blind Trial
Reisberg, ., Ferris, S. H., Anand, R., Mir, P., Geibel, V., de Leon, M. J., & Roberts, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303243081213 · Cited by 151
RELIABILITY AND VALIDITY OF A SCALE FOR ASSESSING THE FUNCTIONING OF GERIATRIC PATIENTS
Plutchik, R., Conte, H. R., Lieberman, M., Bakur, M., Grossman, J., & Lehrman, N. S. (1970) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1970.tb01335.x · Cited by 114
Sim, M., & Sussman, I. (1962) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196212000-00002 · Cited by 113
Apomorphine and Other Dopaminomimetics: Basic Pharmacology, Vol. I
Davis, G. C. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.6.838 · Cited by 109
A Brief Psychogeriatric Assessment Schedule
Pattie, A. H., & Gilleard, C. J. (1975) · The British Journal of Psychiatry · doi:10.1192/bjp.127.5.489 · Cited by 101
Clinical Value of the London Psychogeriatric Rating Scale
Hersch, E. L., Kral, V. A., & Palmer, R. (1978) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1978.tb03682.x · Cited by 100
Enhancement of Memory by Physostigmine
(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011721 · Cited by 99
Flagged first, then by citations
Research works printed but not linked: 14
- Salzman C, 1972, Kochansky GE
- Reisberg B, 1983, The Brief Cognitive Rating Scale (BCRS): findings in primary degenerative dementia (PDD). Psychopharmacol Bull 19: 47-SO
- Cole MG, 1980, Journal of Clinical and Experimental Gerontology, 2, 46
- Mohs RC, 1982, Rosen WG
- Corsellis JAN, 1962, Mental Illness and the Aging Brain
- Coblentz JM, 1973, Presenile dementia: clinical aspects and evaluation of cerebrospinal fluid dynamics. Arch Neurol 29:299-308
- Ajuriaguerra Jd R, 1980, Ciompi L. Berne, Hans Huber
- Mayer-Gross W, 1969, Roth M: Clinical Psychiatry
- Rosen WG, 1982, Alzheimer's Disease: A Report of Progress in Research. Edited by Corkin 5, Davis KL, Growdon JH, et al.
- Goodglass H, 1972, Kaplan E: The Assessment of Aphasia and Related Disorders
- Thorndike EL, 1944, Lorge I: The Teacher's Word Book of 30,000 Words
- Wells CE, 1977, FA Davis
- Guilford JP, 1978, Fruchter B: Fundamental Statistics in Psychology and Education
- Davis KL, 1982, Psychopharmacol Bull, 18, 193
Cited by
Sorted by citations
Items 101–200 of 269
Fiatarone Singh, M. A., Gates, N., Saigal, N., Wilson, G. C., Meiklejohn, J., Brodaty, H., Wen, W., Singh, N., Baune, B. T., Suo, C., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.010 · Cited by 424
A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., & Thal, L. J. (2003) · Sleep · doi:10.1093/sleep/26.7.893 · Cited by 407
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
A total score for the CERAD neuropsychological battery
Chandler, M. J., Lacritz, L. H., Hynan, L. S., Barnard, H. D., Allen, G., Deschner, M., Weiner, M. F., & Cullum, C. M. (2005) · Neurology · doi:10.1212/01.wnl.0000167607.63000.38 · Cited by 387
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Padurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W., & Stefanescu, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.033 · Cited by 378
Swainson, R., Hodges, J. R., Galton, C. J., Semple, J., Michael, A., Dunn, B. D., Iddon, J. L., Robbins, T. W., & Sahakian, B. J. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051269 · Cited by 375
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
The potential effects of meditation on age-related cognitive decline: a systematic review.
Gard, T., Hölzel, B. K., & Lazar, S. W. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12348 · Cited by 363
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356
Effectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging
Nir, T. M., Jahanshad, N., Villalon-Reina, J. E., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.07.006 · Cited by 348
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Pohjasvaara, T., Erkinjuntti, T., Vataja, R., & Kaste, M. (1997) · Stroke · doi:10.1161/01.str.28.4.785 · Cited by 328
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
(2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.09.014 · Cited by 310
Depressive Symptoms and Cognitive Decline in Late Life: A Prospective Epidemiological Study
Ganguli, M., Du, Y., Dodge, H. H., Ratcliff, G. G., & Chang, C.-C. H. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.153 · Cited by 314
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Coping strategies, anxiety and depression in caregivers of people with Alzheimer’s disease
Cooper, C., Katona, C., Orrell, M., & Livingston, G. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2007 · Cited by 307
Riley, K. P., Snowdon, D. A., Desrosiers, M. F., & Markesbery, W. R. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.019 · Cited by 303
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Tieland, M., Borgonjen-Van den Berg, K. J., van Loon, L. J. C., & de Groot, L. C. P. G. M. (2012) · European Journal of Nutrition · doi:10.1007/s00394-011-0203-6 · Cited by 297
Zucchella, C., Sinforiani, E., Tamburin, S., Federico, A., Mantovani, E., Bernini, S., Casale, R., & Bartolo, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01058 · Cited by 297
“A recent meta-analysis showed that CS has a moderate effect size on the Mini Mental State Examination (75) and a small effect size on the Alzheimer’s Disease Assessment Scale-cognitive subscale (76), which represent two commonly-used general cognitive functioning outcomes, in patients with dementia (73).”
MethodHaroutunian, V. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1185 · Cited by 289
Toth, L., Hoffmann, I., Gosztolya, G., Vincze, V., Szatloczki, G., Banreti, Z., Pakaski, M., & Kalman, J. (2018) · Current Alzheimer Research · doi:10.2174/1567205014666171121114930 · Cited by 290
Shinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130722 · Cited by 288
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287
Dichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70046-2 · Cited by 264
Kado, D. M., Karlamangla, A. S., Huang, M.-H., Troen, A., Rowe, J. W., Selhub, J., & Seeman, T. E. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.08.019 · Cited by 268
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Effects of omega-3 fatty acids on cognitive performance: a meta-analysis
Mazereeuw, G., Lanctôt, K. L., Chau, S. A., Swardfager, W., & Herrmann, N. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.014 · Cited by 253
Akhondzadeh, S., Sabet, M. S., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. S., Yousefi, M. H., Alimardani, R., Jamshidi, A., et al. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01133.x · Cited by 249
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Pilot Controlled Trial of Mindfulness Meditation and Education for Dementia Caregivers
Oken, B. S., Fonareva, I., Haas, M., Wahbeh, H., Lane, J. B., Zajdel, D., & Amen, A. (2010) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2009.0733 · Cited by 232
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans
Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234
Transcranial direct current stimulation in severe, drug-resistant major depression
Ferrucci, R., Bortolomasi, M., Vergari, M., Tadini, L., Salvoro, B., Giacopuzzi, M., Barbieri, S., & Priori, A. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.015 · Cited by 228
Sahakian, B. J., Owen, A. M., Morant, N. J., Eagger, S. A., Boddington, S., Crayton, L., Crockford, H. A., Crooks, M., Hill, K., & Levy, R. (1993) · Psychopharmacology · doi:10.1007/bf02244644 · Cited by 226
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
Saji, N., Niida, S., Murotani, K., Hisada, T., Tsuduki, T., Sugimoto, T., Kimura, A., Toba, K., & Sakurai, T. (2019) · Scientific Reports · doi:10.1038/s41598-018-38218-7 · Cited by 224
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
Rafii, M. S., Tuszynski, M. H., Thomas, R. G., Barba, D., Brewer, J. B., Rissman, R. A., Siffert, J., Aisen, P. S., & for the AAV2-NGF Study Team (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0233 · Cited by 219
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
Coping strategies and anxiety in caregivers of people with Alzheimer’s disease: the LASER-AD study
Cooper, C., Katona, C., Orrell, M., & Livingston, G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.08.017 · Cited by 208
Rodakowski, J., Saghafi, E., Butters, M. A., & Skidmore, E. R. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.003 · Cited by 212
Social participation and risk of developing dementia
Sommerlad, A., Kivimäki, M., Larson, E. B., Röhr, S., Shirai, K., Singh-Manoux, A., & Livingston, G. (2023) · Nature Aging · doi:10.1038/s43587-023-00387-0 · Cited by 207
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease
Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., Davis, K. L., & Mohs, R. C. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.713 · Cited by 201
Self-citationGosztolya, G., Vincze, V., Tóth, L., Pákáski, M., Kálmán, J., & Hoffmann, I. (2019) · Computer Speech & Language · doi:10.1016/j.csl.2018.07.007 · Cited by 196
Genome-wide association study of the rate of cognitive decline in Alzheimer’s disease
Sherva, R., Tripodis, Y., Bennett, D. A., Chibnik, L. B., Crane, P. K., de Jager, P. L., Farrer, L. A., Saykin, A. J., Shulman, J. M., Naj, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.008 · Cited by 180
Alcohol consumption and cognitive function in late life: A longitudinal community study
Ganguli, M., Bilt, J. V., Saxton, J. A., Shen, C., & Dodge, H. H. (2005) · Neurology · doi:10.1212/01.wnl.0000180520.35181.24 · Cited by 190
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168
Huntley, J. D., Gould, R. L., Liu, K., Smith, M., & Howard, R. J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-005247 · Cited by 182
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Davis, K. L., & Powchick, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90526-x · Cited by 177
Self-citationCortical Plasticity in Alzheimer’s Disease in Humans and Rodents
Battaglia, F., Wang, H.-Y., Ghilardi, M. F., Gashi, E., Quartarone, A., Friedman, E., & Nixon, R. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.027 · Cited by 175
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Chung, J. A., & Cummings, J. L. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70228-0 · Cited by 174
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
Forlenza, O. V., Radanovic, M., Talib, L. L., & Gattaz, W. F. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2019.76 · Cited by 171
Hogan, D. B., Bailey, P., Black, S., Carswell, A., Chertkow, H., Clarke, B., Cohen, C., Fisk, J. D., Forbes, D., Man-Son-Hing, M., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081103 · Cited by 167
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Optic nerve head and nerve fiber layer in Alzheimer's disease
Tsai, C. S. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080020045040 · Cited by 163
Román, G. C., Salloway, S., Black, S. E., Royall, D. R., DeCarli, C., Weiner, M. W., Moline, M., Kumar, D., Schindler, R., & Posner, H. (2010) · Stroke · doi:10.1161/strokeaha.109.570077 · Cited by 161
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161
Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
Canhada, S., Castro, K., Perry, I. S., & Luft, V. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1321813 · Cited by 156
Initiative, F. T. A. D. N., Skinner, J., Carvalho, J. O., Potter, G. G., Thames, A., Zelinski, E., Crane, P. K., & Gibbons, L. E. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9166-3 · Cited by 151
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802328142 · Cited by 147
Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria
Franzen, S., Smith, J. E., van den Berg, E., Rivera Mindt, M., van Bruchem‐Visser, R. L., Abner, E. L., Schneider, L. S., Prins, N. D., Babulal, G. M., & Papma, J. M. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12433 · Cited by 146
Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials
Román, G. C., Wilkinson, D. G., Doody, R. S., Black, S. E., Salloway, S. P., & Schindler, R. J. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000088494 · Cited by 141
Pitkala, K. H., Routasalo, P., Kautiainen, H., Sintonen, H., & Tilvis, R. S. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181f7d8b0 · Cited by 139
Trajectories of cognitive decline in different types of dementia
Smits, L. L., van Harten, A. C., Pijnenburg, Y. A. L., Koedam, E. L. G. E., Bouwman, F. H., Sistermans, N., Reuling, I. E. W., Prins, N. D., Lemstra, A. W., Scheltens, P., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291714002153 · Cited by 134
Bastos-Leite, A. J., van der Flier, W. M., van Straaten, E. C. W., Staekenborg, S. S., Scheltens, P., & Barkhof, F. (2007) · Stroke · doi:10.1161/strokeaha.107.490102 · Cited by 128
Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.002 · Cited by 128
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Schubert, J. J., Veronese, M., Marchitelli, L., Bodini, B., Tonietto, M., Stankoff, B., Brooks, D. J., Bertoldo, A., Edison, P., & Turkheimer, F. E. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223834 · Cited by 121
Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis
Wang, H., Tan, L., Wang, H.-F., Liu, Y., Yin, R.-H., Wang, W.-Y., Chang, X.-L., Jiang, T., & Yu, J.-T. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143225 · Cited by 123
van Soest, A. P. M., Hermes, G. D. A., Berendsen, A. A. M., van de Rest, O., Zoetendal, E. G., Fuentes, S., Santoro, A., Franceschi, C., de Groot, L. C. P. G. M., & de Vos, W. M. (2020) · Nutrients · doi:10.3390/nu12113471 · Cited by 118
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry
Egger, K., Schocke, M., Weiss, E., Auffinger, S., Esterhammer, R., Goebel, G., Walch, T., Mechtcheriakov, S., & Marksteiner, J. (2008) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2007.12.018 · Cited by 113
Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
Hallschmid, M. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12934 · Cited by 113
Analysis the Link between Periodontal Diseases and Alzheimer’s Disease: A Systematic Review
Borsa, L., Dubois, M., Sacco, G., & Lupi, L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179312 · Cited by 109
The staging and assessment of moderate to severe Alzheimer disease
Feldman, H. H., & Woodward, M. (2005) · Neurology · doi:10.1212/wnl.65.6_suppl_3.s10 · Cited by 105
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub4 · Cited by 104
Metadata
- Authors
- Rosen, W. G., Mohs, R. C., & Davis, K. L.
- Affiliations
- James J. Peters VA Medical Center (US)
- Venue
- American Journal of Psychiatry
- Published
- 1984-11-01
- Volume
- 141
- Issue
- 11
- Pages
- 1356-1364
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1953027527
- Cited by
- 4,175
- References
- 19
- Citations by year
- 2026: 111 · 2025: 129 · 2024: 171 · 2023: 139 · 2022: 149 · 2021: 180 · 2020: 167 · 2019: 149 · 2018: 165 · 2017: 150 · 2016: 129 · 2015: 149 · 2014: 157 · 2013: 160 · 2012: 141
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Keywords
- Alzheimer's disease, Alzheimer's Disease Assessment Scale, rating scale development, cognitive impairment, behavioral dysfunction, disease severity assessment, inter-rater reliability, test-retest reliability, elderly subjects
- MeSH terms
- Aged, Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
